Ascletis Pharma Inc./歌礼生物科技（杭州)有限公司
{{company.company_channel.channel_name}}
Media Room
{{company.company_name_local}}
{{company.company_channel.channel_name}}
Company Profile
Media Room
Ascletis (1672.HK) Included in MSCI China Small Cap Index 2022-05-16 20:17
Ascletis Announces U.S. IND Approval of ASC22 (Envafolimab) for Immune Restoration/Functional Cure of HIV-1 Infected Patients 2022-05-11 08:40
Ascletis Announces 3CLpro Inhibitor ASC11 Demonstrated Potential to be Effective Treatment for COVID-19 2022-04-19 16:50
Ascletis Announces Cooperation with China Meheco International Co., Ltd. in Distribution of Its Ritonavir Tablets in Chinese Mainland 2022-04-13 21:00
Gannex Announces First Patient Dosed in Phase II Clinical Trial of ASC42, an FXR Agonist, for Primary Biliary Cholangitis 2022-04-10 18:20
Ascletis Announces China IND Approval of Its Second FASN Inhibitor ASC60 for Treatment of Advanced Solid Tumors 2022-04-06 17:10
Ascletis Announces Completion of First Sale of Its Ritonavir Tablets in Zhejiang Province 2022-04-04 17:10
Ascletis Announces Submission of Marketing Authorization Application for Ritonavir in Hong Kong 2022-04-03 18:20
Ascletis Announces Completion of Patient Enrollment in Phase II Clinical Trial of ASC42, an In-House Developed, Best-in-Class FXR Agonist for Chronic Hepatitis B Indication 2022-03-30 18:26
Ascletis Announces the Latest Results of the Preclinical Studies of Two Novel Anti-Cancer Drug Candidates, ASC61 and ASC60, to be presented at AACR Annual Meeting 2022 2022-03-27 18:30
Business Update on ASC10, an Oral Double Prodrug against COVID-19 2022-03-15 19:55
Ascletis Announces Further Expansion of Ritonavir Oral Tablet Production Capacity to 530 Million Tablets Per Year 2022-03-13 18:30
Ascletis Announces Submission of Marketing Authorization Applications for Ritonavir in Eight Additional European Countries 2022-03-01 17:30
Shanghai Public Health Clinical Center Initiated Functional Cure Study of Anti-PD-L1 Antibody ASC22 (Envafolimab) in Combination With Chidamide in HIV-Infected Patients 2022-02-14 17:34
Ascletis Announces Submission of Marketing Authorization Applications for Ritonavir in Multiple European Countries 2022-02-13 18:30
Ascletis Announces Positive Data of Oral Double Prodrug ASC10 and Its Antiviral Nucleoside Analog ASC10-A Against Omicron Variant 2022-02-07 19:00
Ascletis Announces U.S. IND Approval of Oral PD-L1 Small Molecule Inhibitor ASC61 for Treatment of Advanced Solid Tumors 2022-02-06 18:30
Ascletis Announces IND Filing of Its Second FASN Inhibitor ASC60 for Advanced Solid Tumors Accepted by China NMPA 2022-01-26 19:00
Ascletis Announces First Patient Dosed in the Phase III Clinical Trial of FASN Inhibitor ASC40 Combined with Bevacizumab for Treatment of Recurrent Glioblastoma 2022-01-23 18:35
Ascletis Announces Signing of Ritonavir Tablet Purchase Agreement with Phokam Pharmaceutical Import-Export Co., Ltd of Laos 2022-01-18 18:00
1 2 3 4 5 6 9